Citations

Showing 10 of 108081 citations.

Dietary restriction but not angiotensin II type 1 receptor blockade improves DNA damage-related vasodilator dysfunction in rapidly agingErcc1Δ/−mice
Wu, Haiyan , Thiel, Bibi S. van, Bautista‐Niño, Paula K. , Reiling, Erwin, Durik, Matej , Leijten, Frank, Ridwan, Yanto, Brandt, Renata M. C. , Steeg, Harry van , Vermeij, Wilbert P. , Essers, Jeroen , Pluijm, Ingrid van der , Roks, Anton J.M. , Dollé, Martijn E.T. , Hoeijmakers, Jan H.J. , Danser, A.H. Jan

Mayo Clinic

Clinical Science | June 16, 2017 | Volume: 131 | Issue: 15 | Pages: 1941-1953

10.1042/cs20170026 | PMID 28620011 Get It

DNA damage is an important contributor to endothelial dysfunction and age-related vascular disease. Recently, we demonstrated in a DNA repair-deficient, prematurely aging mouse model (Ercc1Δ/− mice) that dietary restriction (DR) strongly increases life- and health span, including ameliorating endothelial dysfunction, by preserving genomic integrity. In this mouse mutant displaying prominent accelerated, age-dependent endothelial dysfunction we investigated the signaling pathways involved in improved endothelium-mediated vasodilation by DR, and explore the potential role of the renin-angiotensin system (RAS). Ercc1Δ/− mice showed increased blood pressure and decreased aortic relaxations to acetylcholine (ACh) in organ bath experiments. Nitric oxide (NO) signaling and phospho-Ser1177-eNOS were compromised in Ercc1Δ/−. DR improved relaxations by increasing prostaglandin-mediated responses. Increase of cyclo-oxygenase 2 and decrease of phosphodiesterase 4B were identified as potential mechanisms. DR also prevented loss of NO signaling in vascular smooth muscle cells and normalized angiotensin II (Ang II) vasoconstrictions, which were increased in Ercc1Δ/− mice. Ercc1Δ/− mutants showed a loss of Ang II type 2 receptor-mediated counter-regulation of Ang II type 1 receptor-induced vasoconstrictions. Chronic losartan treatment effectively decreased blood pressure, but did not improve endothelium-dependent relaxations. This result might relate to the aging-associated loss of treatment efficacy of RAS blockade with respect to endothelial function improvement. In summary, DR effectively prevents endothelium-dependent vasodilator dysfunction by augmenting prostaglandin-mediated responses, whereas chronic Ang II type 1 receptor blockade is ineffective.
Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas
Hardell, Elin, Josefson, Sofia, Ghaderi, Mehran , Skeie-Jensen, Tone, Westbom-Fremer, Sofia , Cheek, Elizabeth, Bell, Debra, Selling, Jonas, Schoolmeester, John K., Måsbäck, Anna , Davidson, Ben , Carlson, Joseph W. , Carlson, Joseph W

Mayo Clinic

American Journal of Surgical Pathology | June 15, 2017 | Volume: 41 | Issue: 9 | Pages: 1231-1237

10.1097/pas.0000000000000894 | PMID 28622181 Get It

Undifferentiated uterine sarcomas (UUS) are a heterogenous group of high-grade mesenchymal tumors. Although these tumors are highly aggressive, a subset of patients may experience long-term survival. These tumors have previously been divided morphologically into uniform and pleomorphic types. A previous study demonstrated that a mitotic index cutoff of 25 mitoses/10 high-power fields (corresponding to 11.16 mitotic figures/mm2) could successfully divide tumors into 2 prognostic groups with significantly different overall survival. The goals of the current study were to (1) validate this mitotic index cutoff in an independent, multicenter cohort and (2) explore the prognostic value of the mitotic index groups in relation to other clinicopathologic variables. Cases were included from 3 independent institutions: The Norwegian Radium Hospital, The Mayo Clinic, and Skåne University Hospital. A total of 40 tumors were included after central review. All cases were negative for the YWHAE-FAM22A/B and JAZF1-JJAZ1 translocations. Survival data were available on all patients. In this study, one-third of patients with UUS survived beyond 5 years. The crude (unadjusted) Cox Proportional Hazards model revealed a number of parameters that significantly impacted overall survival, including mitotic index group, patient age, stage, and the presence of tumor necrosis. Classification into the uniform and pleomorphic types was not prognostic. Combining these parameters into an adjusted model revealed that only the mitotic index group and stage were prognostic. On the basis of these findings, it is proposed that UUS be subdivided into “mitogenic” and “not otherwise specified” types.
Paucicellular Fibrointimal Proliferation Characterizes Pediatric Pulmonary Vein Stenosis
Kovach, Alexandra E. , Magcalas, Philip M., Ireland, Christina M. , McEnany, Kerry, Oliveira, André M. , Baird, Christopher W. , Vargas, Sara O. , Kieran, Mark W. , Jenkins, Kathy J. , Kovach, Alexandra E

Mayo Clinic

American Journal of Surgical Pathology | June 15, 2017 | Volume: 41 | Issue: 9 | Pages: 1198-1204

10.1097/pas.0000000000000892 | PMID 28622179 Get It

Pulmonary vein stenosis (PVS) is a luminal narrowing of extrapulmonary pulmonary veins. In pediatric patients, it arises following repair of congenital heart disease, particularly anomalous pulmonary venous return; in lung disease, especially prematurity; and rarely in isolation. The etiology is unknown and the course often fatal without lung transplantation. We hypothesized that systematic clinicopathologic review of pediatric PVS could provide further pathogenic insight. We included patients who underwent first resection of pulmonary venous tissue for symptomatic PVS at our pediatric referral center from 1995 to 2014. Clinical records and hematoxylin and eosin slides were reviewed. Subsets were immunostained for smooth muscle actin, Ki-67, β-catenin, estrogen receptor, and other markers and analyzed forUSP6gene rearrangement. A total of 97 patients (57% male; median age: 6 mo) were identified. Overall, 59 (61%) had prior congenital heart disease repair, 35 involving pulmonary vein manipulation. Samples included 213 separate anatomic sites (median: 2/patient). Histologically, all showed sparsely cellular intimal expansion composed of haphazardly arranged fibroblasts with slender nuclei in myxoid matrix. This tissue merged with underlying collagen. Most samples had a variably continuous sheath of cardiomyocytes. Ancillary tests supported a reactive fibroblastic proliferation; in particular, fibroblasts showed cytoplasmic β-catenin localization, no estrogen receptor expression, and noUSP6rearrangement. At last follow-up (mean: 2.3 y), 46% of patients had died of disease. Pediatric PVS uniformly consists of a paucicellular fibrointimal proliferation, irrespective of clinical scenario. It may be best conceived of as a form of reactive hyperplasia. As with other forms of vascular remodeling, trauma (iatrogenic or occult) is likely an inciting factor. A comprehensive understanding of the surgical pathology of PVS may further inform therapeutic strategies in this lethal disease.
Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci
Glubb, Dylan M. , Group, the AGO Study, Johnatty, Sharon E. , Quinn, Michael C. , O’Mara, Tracy A. , Gao, Bo , Fasching, Peter A. , Beckmann, Matthias W. , Lambrechts, Diether , Vergote, Ignace , Beeghly‐Fadiel, Alicia, Benı́tez, Javier , García, María J. , Goodman, Marc T. , Thompson, Pamela J., Dörk, Thilo , Modungo, Francesmary, Moysich, Kirsten B. , Heitz, Florian , Pfisterer, Jacobus , Hillemanns, Peter , Lester, Jenny, Goode, Ellen L. , Cunningham, Julie M. , McCauley, Bryan M. , Jensen, Allan , Schildkraut, Joellen M. , Terry, Kathryn L. , Salvesen, Helga B., Webb, Penny M., Grant, Peter J. , Moffitt, Melissa , Høgdall, Claus , Paul, James, Bernardini, Marcus Q. , Tone, Alicia , Huntsman, David, Woo, Michelle, Group, AOCS, DeFazio, Anna , Kennedy, Catherine J. , MacGregor, Stuart , Chenevix‐Trench, Georgia , Webb, Penelope M. , Bowtell, David D.L. , Lambrechts, Diether , Winham, Stacey J. , Fazio, Anna de , Group, the AGO Study, Tyrer, Jonathan P. , Edwards, Digna R. Velez , Beeghly‐Fadiel, Alicia , Dürst, Matthias , Bois, Andreas du , Karlan, Beth Y. , Larson, Melissa C. , Kjær, Susanne K. , Berchuck, Andrew , Cramer, Daniel W. , Bjørge, Line , Webb, Penny M., Pejovic, Tanja B. , Høgdall, Estrid , Glasspool, Rosalind , Group, AOCS, Pharoah, Paul D.P. , Dörk, Thilo , Lambrechts, Diether , Webb, Penelope M , Hillemanns, Peter , Jensen, Allan , Moysich, Kirsten , Kennedy, Catherine J , O'Mara, Tracy A , Heitz, Florian , Lambrechts, Diether , Quinn, Michael C J , MacGregor, Stuart , Benitez, Javier , Chenevix-Trench, Georgia , Høgdall, Claus K , Bowtell, David D , Goodman, Marc T

Mayo Clinic

Oncotarget | June 15, 2017 | Volume: 8 | Issue: 39 | Pages: 64670-64684

10.18632/oncotarget.18501 | PMID 29029385 Get It

Thoracic Imaging After Bariatric Surgery
Sonavane, Sushilkumar K. , Sanyal, Rupan , Singh, Satinder P. , Menias, Christine O. , Galgano, Samuel J, Galgano, Samuel Joseph , Bhalla, Sanjeev

Mayo Clinic

Journal of Thoracic Imaging | June 15, 2017 | Volume: 32 | Issue: 5 | Pages: W45-W53

10.1097/rti.0000000000000286 | PMID 28622165 Get It

Obesity and its association with long-term health problems constitutes one of the major challenges in medicine. Though diet regulation and exercise are the primary treatment strategies, surgery is the most reliable long-term solution. Although bariatric surgical complications continue to decline, prompt recognition is essential to optimize patient outcomes. Despite their relative rarity, it is important to recognize thoracic complications, as several of these can result in severe morbidity and mortality. This article describes common bariatric surgical procedures performed, their expected postoperative appearances, and intrathoracic complications.
Extraskeletal Osteosarcoma
Fritchie, Karen , Haddox, Candace L. , Rose, Peter S. , Arndt, Carola A.S., Marks, Randolph S., Okuno, Scott H. , Paludo, Jonas , Galanis, Evanthia , Robinson, Steven I. , Haddox, Candace L

Mayo Clinic

American Journal of Clinical Oncology | June 15, 2017 | Volume: 41 | Issue: 9 | Pages: 832-837

10.1097/coc.0000000000000397 | PMID 28622153 Get It

Objectives: Extraskeletal osteosarcoma (EO) is a malignant neoplasm that produces osteoid, bone, and chondroid material without direct attachment to bone or periosteum. Surgical resection is the mainstay of treatment; the role of chemotherapy is not well defined. Therefore, we evaluated the impact of chemotherapy in the survival of patients with EO. Methods: All EO patients seen at Mayo Clinic between 1990 and 2014 were assessed. Forty-three patients were included after all archived pathology slides were reviewed to confirm the diagnosis of EO. Results: Of 43 patients, 37 patients had localized disease and 6 patients had metastatic disease at diagnosis. Chemotherapy was used in 73% and 75% of patients, respectively. Chemotherapy was predominantly anthracycline based, and included platinum in 22 patients (84%). Median overall survival (OS) and progression-free survival (PFS) were 50 months (95% confidence interval, 25-99), and 21 months (95% confidence interval, 13-not reached), respectively. There was a trend towards longer OS and PFS in patients who received chemotherapy. Those who received platinum-based therapy had remarkably prolonged OS (median, 182 vs. 18 mo; 5-year, 61% vs. 0%; P=0.01) and PFS (median, not reached vs. 10 mo; 5-year, 56% vs. 0%; P=0.005). Baseline characteristics were similar in the platinum and nonplatinum group. In patients who received chemotherapy, relapse/recurrence rate was lower in the platinum-based group (41%) as opposed to the nonplatinum-based group (100%; P=0.02). In the neoadjuvant setting, the overall response rate of platinum-containing regimens was 27%. Conclusions: Our results suggest a clinical benefit when platinum-based chemotherapy is incorporated in the management of patients with EO. We plan to validate this further with an expanded multicenter analysis.
Effect of position, time in the season, and playing surface on Achilles tendon ruptures in NFL games: a 2009-10 to 2016-17 review
Krill, Michael K. , Borchers, James, Hoffman, Joshua, Krill, Matthew L., Hewett, Timothy E.

Mayo Clinic

The Physician and Sportsmedicine | June 15, 2017 | Volume: 45 | Issue: 3 | Pages: 259-264

10.1080/00913847.2017.1343652 | PMID 28617627 Get It

Improved localization, spectral quality, and repeatability with advanced MRS methodology in the clinical setting
Deelchand, Dinesh K. , Kantarci, Kejal , Öz, Gülin , Öz, Gülin , Kantarci, Kejal , Deelchand, Dinesh K

Mayo Clinic

Magnetic Resonance in Medicine | June 15, 2017 | Volume: 79 | Issue: 3 | Pages: 1241-1250

10.1002/mrm.26788 | PMID 28618085 Get It

PurposeTo investigate the utility of an advanced magnetic resonance spectroscopy (MRS) protocol in the clinical setting, and to compare the localization accuracy, spectral quality, and quantification repeatability between this advanced and the conventional vendor‐provided MRS protocol on a clinical 3T platform.MethodsProton spectra were measured from the posterior cingulate cortices in 30 healthy elderly subjects by clinical MR technologists using a vendor‐provided (point resolved spectroscopy with advanced 3D gradient‐echo B0 shimming) and an advanced (semi‐LASER with FAST(EST)MAP shimming) protocol, in random order. Spectra were quantified with LCModel using standard pipelines for the clinical and research settings, respectively.ResultsThe advanced protocol outperformed the vendor‐provided protocol in localization accuracy (chemical‐shift‐displacement error: 2.0%/ppm, semi‐LASER versus 11.6%/ppm, point resolved spectroscopy), spectral quality (water linewidth: 6.1 ± 1.8 Hz, FAST(EST)MAP versus 10.5 ± 3.7 Hz, 3D gradient echo; P < 7e‐6; residual water: 0.08 ± 0.12%, VAPOR versus 0.45 ± 0.50%, WET; P < 2e‐5) and within‐session repeatability of metabolite concentrations, particularly of low signal‐to‐noise ratio data with two to eight averages (test‐retest coefficients of variance of metabolite concentrations, P < 0.01). Concentrations of J‐coupled metabolites such as γ‐aminobutyric acid and glutamate were biased when using the default pipeline with simulated macromolecules.ConclusionsThe quality of MRS data can be improved using advanced acquisition and analysis protocols on standard 3T hardware in the clinical setting, which can facilitate robust applications in central nervous system diseases. Magn Reson Med 79:1241–1250, 2018. © 2017 International Society for Magnetic Resonance in Medicine.
Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study
Jian‐Yu, E , Lu, Shou‐En , Graber, Judith M. , Rotter, David , Zhang, Lanjing , Petersen, Gloria M. , Demissie, Kitaw , Lu‐Yao, Grace L. , Tan, Xiang-Lin, Lin, Yong , Tan, Xiang‐Lin

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 15, 2017 | Volume: 26 | Issue: 8 | Pages: 1225-1232

10.1158/1055-9965.epi-17-0227 | PMID 28619830 Get It

Abstract Background: Published evidence indicates that individual use of metformin and statin is associated with reduced cancer mortality. However, their differential and joint effects on pancreatic cancer survival are inconclusive. Methods: We identified a large population-based cohort of 12,572 patients ages 65 years or older with primary pancreatic ductal adenocarcinoma (PDAC) diagnosed between 2008 and 2011 from the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database. Exposure to metformin and statins was ascertained from Medicare Prescription Drug Event files. Cox proportional hazards models with time-varying covariates adjusted for propensity scores were used to assess the association while controlling for potential confounders. Results: Of 12,572 PDAC patients, 950 (7.56%) had used metformin alone, 4,506 (35.84%) had used statin alone, and 2,445 (19.45%) were dual users. Statin use was significantly associated with improved overall survival [HR, 0.94; 95% confidence interval (CI), 0.90–0.98], and survival was more pronounced in postdiagnosis statin users (HR, 0.69; 95% CI, 0.56–0.86). Metformin use was not significantly associated with overall survival (HR, 1.01; 95% CI, 0.94–1.09). No beneficial effect was observed for dual users (HR, 1.00; 95% CI, 0.95–1.05). Conclusions: Our findings suggest potential benefits of statins on improving survival among elderly PDAC patients; further prospective studies are warranted to corroborate the putative benefit of statin therapy in pancreatic cancer. Impact: Although more studies are needed to confirm our findings, our data add to the body of evidence on potential anticancer effects of statins. Cancer Epidemiol Biomarkers Prev; 26(8); 1225–32. ©2017 AACR.